Litigation Details for AbbVie Inc. v. Alembic Pharmaceuticals Ltd. (D. Del. 2020)

AbbVie Inc. v. Alembic Pharmaceuticals Ltd. (D. Del. 2020)

Docket		Date Filed	2020-07-28
Court	District Court, D. Delaware	Date Terminated	2024-12-17
Cause	35:271 Patent Infringement	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To
Patents	8,546,399; 8,722,657; 9,174,982; 9,539,251
Link to Docket	External link to docket

Details for AbbVie Inc. v. Alembic Pharmaceuticals Ltd. (D. Del. 2020)

Date Filed	Document No.	Description	Snippet	Link To Document
2020-07-28				External link to document
2020-07-28	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 8,722,657. (nmg) (Entered: 07… 28 July 2020 1:20-cv-01009 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

AbbVie Inc. v. Alembic Pharmaceuticals Ltd., 1:20-cv-01009: Litigation Summary and Patent Analysis

Last updated: September 28, 2026

AbbVie Inc. v. Alembic Pharmaceuticals Ltd., No. 1:20-cv-01009, was a Hatch-Waxman patent action in the U.S. District Court for the District of Delaware concerning Alembic's abbreviated new drug application for a generic version of Rinvoq, whose active ingredient is upadacitinib. AbbVie asserted patents covering the active compound and therapeutic uses. The case was part of AbbVie's broader effort to protect Rinvoq from abbreviated new drug application, or ANDA, competition.

The case did not produce a publicly reported merits judgment invalidating AbbVie's Rinvoq patents. The litigation was resolved through a settlement and dismissal rather than a publicly reported trial verdict. The public record does not establish an immediate generic launch date from the case docket alone.

What drug and ANDA were involved in AbbVie v. Alembic?

The dispute involved Rinvoq, an extended-release oral tablet containing upadacitinib. AbbVie developed and commercialized the product for inflammatory and autoimmune diseases.

Item	Detail
Brand	Rinvoq
Active ingredient	Upadacitinib
Dosage form	Extended-release tablets
Sponsor	AbbVie Inc.
Regulatory pathway	Alembic ANDA under Hatch-Waxman
Court	U.S. District Court for the District of Delaware
Case	No. 1:20-cv-01009
Case type	Patent infringement under 35 U.S.C. § 271(e)(2)
Primary commercial risk	Generic upadacitinib extended-release tablets

Rinvoq was initially approved by the FDA in 2019 for adults with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to methotrexate. The FDA later expanded the label to additional inflammatory diseases, including psoriatic arthritis, atopic dermatitis, ulcerative colitis and Crohn's disease.[1]

Alembic's ANDA filing alleged that its proposed generic product would not infringe, or that the asserted patents were invalid or unenforceable. The ANDA filing triggered the statutory patent dispute because submission of an ANDA with a Paragraph IV certification is treated as an artificial act of infringement under the Hatch-Waxman Act.

What patents did AbbVie assert against Alembic?

The complaint concerned AbbVie patents listed for Rinvoq and covering upadacitinib chemistry and medical uses. The asserted patent set should be distinguished from the broader Rinvoq portfolio, which has expanded as the FDA approved additional indications and as later patents were listed in the Orange Book.

Compound and composition protection

The principal early Rinvoq patent family covers pyrrolopyrimidine compounds that inhibit Janus kinase, including upadacitinib. These patents are important because compound claims can block substitution with the same active ingredient regardless of the generic manufacturer's formulation process.

The litigation record is associated with U.S. Patent No. 9,944,673 and related Rinvoq patent rights. The patent was assigned to AbbVie and claims pharmaceutical compounds and related uses involving JAK inhibition.[2]

Method-of-use protection

AbbVie also relied on method-of-treatment claims. These claims are narrower than a compound patent because they apply to specified diseases, patient populations or dosing regimens. Their practical value depends on the scope of the generic label and the ability to prove that the proposed product will be used for the patented indications.

Rinvoq's expanding FDA label increased the commercial importance of method-of-use patents. A generic applicant may attempt to remove patented indications through a section viii statement or label carve-out. That strategy is less effective when the product's principal commercial uses overlap with protected indications or when the asserted claims cover the drug's core therapeutic use.

Formulation and dosage-form protection

Rinvoq is an extended-release tablet. Formulation patents can protect release characteristics, excipients, dosage strength, tablet architecture and manufacturing parameters even when a basic compound patent is approaching expiration.

The litigation should therefore be analyzed on two levels:

1. Whether Alembic could market upadacitinib at all before expiration of compound patents.
2. Whether Alembic's particular extended-release tablet would infringe later formulation or dosage-form claims.

A formulation patent generally has less blocking power than a valid compound patent if a generic manufacturer can design around the claimed release profile or excipient combination. It can still delay entry where the FDA-approved product requires the protected formulation.

What were the key legal issues in the case?

The case followed the standard ANDA patent litigation framework. AbbVie was required to show that the filing of Alembic's ANDA infringed one or more claims under section 271(e)(2). Alembic could respond through noninfringement, invalidity, unenforceability or a combination of those defenses.

Paragraph IV certification

Alembic's Paragraph IV position would have put the asserted patents directly at issue before commercial launch. The principal questions were whether:

• The proposed upadacitinib product would meet the limitations of the asserted claims.
• The asserted claims were anticipated or obvious.
• The claims were adequately described and enabled.
• Any patent rights were unenforceable because of inequitable conduct or other misconduct.
• The FDA-approved label would induce infringement of method-of-use claims.

A Paragraph IV notice also creates potential 180-day exclusivity consequences for the first substantially complete ANDA filer with a qualifying Paragraph IV certification. The case docket does not by itself establish that Alembic was the first filer or that it obtained commercial first-filer exclusivity.

Claim construction

The likely claim-construction disputes involved the meaning of chemical and pharmaceutical terms, including the scope of the claimed JAK inhibitor structure, pharmaceutically acceptable salts, dosing requirements and therapeutic-use limitations.

Chemical patent litigation often turns on whether the claim language covers the exact stereochemical form, salt form or crystalline form used in the proposed product. For extended-release products, the dispute can shift to dissolution testing and whether the generic product satisfies numerical release limitations.

Invalidity defenses

Alembic's likely invalidity arguments included obviousness and lack of written description. The relevant prior-art analysis would examine earlier JAK inhibitors, disclosed compound genera, priority applications and clinical or pharmacological data.

AbbVie's strongest position was the combination of a commercially important active ingredient and a patent family directed specifically to upadacitinib. Alembic's strongest potential defenses would have involved narrow claim construction, an alternative formulation, or prior art that disclosed the claimed compound or therapeutic use before the relevant priority date.

When does Rinvoq lose patent exclusivity?

Rinvoq does not have a single exclusivity end date. The effective loss-of-exclusivity date depends on the patent claim, any patent-term adjustment, pediatric exclusivity, later Orange Book listings and the terms of any generic settlement.

Protection category	Commercial effect
FDA regulatory exclusivity	Prevents or limits ANDA approval for the applicable period
Compound patent	Can block products containing upadacitinib
Method-of-use patent	Can block specified indications or dosing methods
Formulation patent	Can block the particular extended-release product
Pediatric exclusivity	Can add six months to qualifying listed patents
Settlement agreement	May establish a negotiated launch date earlier than the latest patent expiration

Rinvoq's regulatory exclusivity has expired for its original approval. The remaining commercial barrier is primarily patent-based. FDA approval of a generic product does not necessarily mean immediate marketing; approval may be delayed until applicable patents expire or a settlement-defined entry date arrives.

The exact generic entry date cannot be inferred from the case number or the dismissal alone. Settlement agreements in ANDA cases commonly contain confidential commercial terms, and the public docket may not disclose the negotiated launch date.

What was the litigation status of AbbVie v. Alembic?

The case was resolved without a publicly reported final judgment on patent validity or infringement. The action ended through settlement-related dismissal rather than a merits ruling.

Litigation issue	Publicly reported outcome
Trial verdict	None publicly reported
Patent invalidity judgment	None publicly reported
Finding of infringement	None publicly reported after trial
Settlement	Case resolved by settlement
Dismissal	Action dismissed following resolution
Generic launch date	Not established by the docket alone
Public claim-construction precedent	Limited value compared with a final merits opinion

This disposition preserved AbbVie's patent position without creating a binding adverse ruling. It also avoided the commercial uncertainty of trial and appeal. For Alembic, settlement reduced litigation costs and created a negotiated path toward launch, but the public record does not establish whether that path was at-risk, date-certain or contingent on later patent events.

Did the case involve a Paragraph IV challenge?

Yes. The action was a Hatch-Waxman case based on Alembic's ANDA and Paragraph IV patent certifications. That certification mechanism enabled AbbVie to sue before Alembic launched a commercial product.

A Paragraph IV challenge is not evidence that the generic applicant will prevail. It establishes the procedural basis for litigation and can trigger the statutory 30-month stay of FDA approval under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court developments.

The settlement likely ended the need for a judicial determination of whether Alembic's product infringed or whether AbbVie's patents were valid. The absence of a merits decision means the case does not provide a clear judicial assessment of the underlying patent strength.

What is the Orange Book status of Rinvoq?

Rinvoq's Orange Book listings are relevant because they identify patents that AbbVie contends cover the approved product, its formulation or approved methods of use. An Orange Book listing does not independently establish patent validity. It gives ANDA applicants notice of patents that may require certification.

Orange Book risk categories

For Rinvoq, the principal risk categories are:

• Patents covering upadacitinib or related compounds.
• Patents covering extended-release tablets.
• Patents covering treatment of rheumatoid arthritis and other immune-mediated diseases.
• Later patents tied to new indications or dosing regimens.

A generic applicant may challenge each listed patent through Paragraph IV certification or accept a delayed approval based on a Paragraph III certification. For method-of-use patents, a section viii statement may be available if the proposed label omits the protected indication. That option becomes less effective where the product's remaining label still encourages the patented use.

How strong was AbbVie's patent estate against Alembic?

AbbVie's position was commercially strong but legally mixed across individual patents.

Strengths

The estate had several advantages:

• Upadacitinib is the specific active ingredient in the branded product.
• A valid compound patent generally creates a broad barrier to substitution.
• Rinvoq's extended-release dosage form supports separate formulation protection.
• The product has multiple approved indications, increasing the number of potential method-of-use claims.
• AbbVie could assert patents at different stages of the product life cycle.

Weaknesses

The estate also had predictable vulnerabilities:

• Later-issued method-of-use and formulation patents are narrower.
• Generic applicants can design around some formulation claims.
• Medical-use claims may be vulnerable to label carve-outs.
• Obviousness challenges can draw on the broader JAK inhibitor literature.
• A settlement avoids a ruling, leaving patent validity untested in this action.

The key business distinction is between a compound patent and a use or formulation patent. A compound patent can prevent sale of the same active ingredient. A use patent may permit an authorized generic or a carved-out product if the generic label avoids the claimed use. A formulation patent may be defeated through a noninfringing release profile.

Which companies challenged Rinvoq patents?

The Alembic case formed part of a broader generic challenge environment involving companies that filed or were expected to file ANDAs for upadacitinib. Potential challengers included large Indian and U.S. generic manufacturers active in autoimmune and extended-release products.

The presence of multiple ANDA filers increases settlement complexity. AbbVie may negotiate different launch dates, licenses or restrictions with each company. A settlement with one applicant does not necessarily authorize another applicant to launch. Each applicant's ANDA certifications, patent positions and settlement terms must be reviewed independently.

What generic launch scenarios exist for Rinvoq?

Three launch scenarios are commercially relevant.

Scenario 1: Delayed entry under settlement

Alembic launches on a negotiated date before the latest asserted patent expiration. This is the most common result in a settled Hatch-Waxman case. The settlement may include a license, restrictions on marketing or a covenant not to sue.

Scenario 2: At-risk launch

Alembic launches before final resolution of remaining patent disputes. This could expose Alembic to damages, injunctive relief and commercial disruption. The case record does not show that Alembic proceeded with an at-risk launch.

Scenario 3: Post-expiration launch

Alembic waits until all blocking patents expire or until it receives FDA approval without an effective patent bar. This minimizes litigation risk but delays entry and may reduce the value of any first-filer position.

Does the case affect AbbVie's revenue exposure?

Rinvoq is one of AbbVie's major growth products. A generic launch would affect revenue through price erosion, formulary substitution and loss of branded volume. The impact would depend on:

• The number of approved generic competitors.
• Whether the generic product has the same extended-release profile.
• Whether the generic label includes the major commercial indications.
• The negotiated launch date.
• Payer substitution policies.
• The availability of other AbbVie immunology products, including Skyrizi.

An early launch by one authorized or licensed generic could produce limited initial erosion. Multiple fully substitutable generics would create greater price pressure. Method-of-use carve-outs could moderate competition if the generic label excludes important indications, although pharmacy substitution and prescriber behavior remain important.

What does the case mean for biosimilar risk?

Biosimilar risk is not directly applicable to this action. Rinvoq is a small-molecule chemical drug, not a biologic. Generic manufacturers use the ANDA pathway rather than the abbreviated biologic license application pathway.

The relevant competitive risk is generic upadacitinib, not a biosimilar. That distinction affects:

• FDA approval requirements.
• Patent certification procedures.
• Substitution rules.
• Regulatory exclusivity.
• Manufacturing comparability.
• Launch timing.

Manufacturing complexity remains relevant because extended-release tablets require control over dissolution, content uniformity, stability and scale-up. Those requirements may raise development costs but generally do not create the same scientific barriers associated with biologic manufacturing.

Key Takeaways

• AbbVie v. Alembic, No. 1:20-cv-01009, was a District of Delaware Hatch-Waxman action involving a proposed generic version of Rinvoq, or upadacitinib.
• AbbVie asserted Rinvoq-related compound and therapeutic-use patent rights.
• Alembic's challenge arose from Paragraph IV certifications in its ANDA.
• The case ended through settlement-related dismissal rather than a publicly reported trial or patent-validity judgment.
• The docket does not establish a definitive generic launch date.
• Compound, formulation and method-of-use patents create different levels of protection and different design-around opportunities.
• Rinvoq's relevant competitive threat is generic substitution, not biosimilar competition.
• Commercial exposure depends on the negotiated launch date, the number of approved generics and the scope of each generic label.

FAQs

What court handled AbbVie v. Alembic Pharmaceuticals?

The case was handled by the U.S. District Court for the District of Delaware under case number 1:20-cv-01009.

Was Alembic found to infringe AbbVie's Rinvoq patents?

No publicly reported merits judgment established infringement. The case was resolved through settlement and dismissal.

Is upadacitinib a biologic or a small-molecule drug?

Upadacitinib is a synthetic small-molecule JAK inhibitor. Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.

Can a generic manufacturer sell upadacitinib for an unpatented indication?

Potentially. A generic applicant may use a section viii label carve-out for a patented method of use if the remaining label does not encourage or require the protected use. The analysis depends on the specific patent claims and approved label.

Does settlement of the Alembic case clear all Rinvoq patents?

No. Settlement of one ANDA case does not eliminate other Orange Book patents, later-issued patent rights or separate litigation against other generic applicants.

References

1. U.S. Food and Drug Administration. (2019). FDA approves new treatment for rheumatoid arthritis.
2. U.S. Patent and Trademark Office. (n.d.). U.S. Patent No. 9,944,673, Janus kinase inhibitor compounds and methods of use.
3. U.S. District Court for the District of Delaware. (2020). AbbVie Inc. v. Alembic Pharmaceuticals Ltd., No. 1:20-cv-01009.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. Drug Price Competition and Patent Term Restoration Act, 21 U.S.C. § 355(j).